Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) VP Jaye Thompson acquired 800 shares of the stock in a transaction that occurred on Monday, August 12th. The shares were bought at an average cost of $13.85 per share, for a total transaction of $11,080.00. Following the completion of the transaction, the vice president now directly owns 263,148 shares of the company's stock, valued at approximately $3,644,599.80. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.
Jaye Thompson also recently made the following trade(s):
- On Friday, August 2nd, Jaye Thompson bought 1,000 shares of Greenwich LifeSciences stock. The stock was bought at an average price of $15.15 per share, with a total value of $15,150.00.
- On Thursday, July 18th, Jaye Thompson purchased 1,000 shares of Greenwich LifeSciences stock. The shares were bought at an average price of $16.00 per share, for a total transaction of $16,000.00.
Greenwich LifeSciences Stock Performance
Shares of NASDAQ GLSI opened at $14.44 on Tuesday. The business has a 50 day simple moving average of $14.64 and a 200 day simple moving average of $15.11. Greenwich LifeSciences, Inc. has a 52 week low of $7.58 and a 52 week high of $21.44. The stock has a market cap of $185.99 million, a price-to-earnings ratio of -20.06 and a beta of 1.61.
Kamala Harris To Tank the Market?
From Paradigm Press | Ad
URGENT ELECTION MELTDOWN WARNING
From the former CIA advisor who predicted President Trump’s win in 2016…
Click here now to see how to protect yourself.
Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) last posted its earnings results on Wednesday, August 14th. The company reported ($0.20) EPS for the quarter, hitting the consensus estimate of ($0.20). On average, analysts predict that Greenwich LifeSciences, Inc. will post -0.81 EPS for the current year.
Analysts Set New Price Targets
Separately, HC Wainwright lifted their price objective on Greenwich LifeSciences from $36.00 to $38.00 and gave the company a "buy" rating in a research report on Friday, August 23rd.
View Our Latest Analysis on GLSI
Hedge Funds Weigh In On Greenwich LifeSciences
Several hedge funds have recently bought and sold shares of GLSI. Vanguard Group Inc. lifted its position in shares of Greenwich LifeSciences by 0.6% in the first quarter. Vanguard Group Inc. now owns 223,102 shares of the company's stock worth $4,449,000 after buying an additional 1,420 shares during the last quarter. Rhumbline Advisers bought a new position in shares of Greenwich LifeSciences in the 2nd quarter valued at approximately $117,000. Finally, Bank of New York Mellon Corp acquired a new stake in Greenwich LifeSciences in the 2nd quarter worth approximately $264,000. 4.16% of the stock is owned by institutional investors and hedge funds.
Greenwich LifeSciences Company Profile
(
Get Free Report)
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
